The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
Abstract
BACKGROUND: The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO closure combined with antiplatelet therapy versus antiplatelet therapy alone on the risks of recurrent stroke and new brain infarctions. METHODS: In this multinational trial involving patients with a PFO who had had a cryptogenic stroke, we randomly assigned patients, in a 2:1 ratio, to undergo PFO closure plus antiplatelet therapy (PFO closure group) or to receive antiplatelet therapy alone (antiplatelet-only group). Imaging of the brain was performed at the baseline screening and at 24 months. The coprimary end points were freedom from clinical evidence of ischemic stroke (reported here as the percentage of patients who had a recurrence of stroke) through at least 24 months after randomization and the 24-month incidence of new brain infarction, which was a composite of clinical ischemic stroke or silent brain infarction detected on imaging. RESULTS: We enrolled 664 patients (mean age, 45.2 years), of whom 81% had moderate or large interatrial shunts. During a median follow-up of 3.2 years, clinical ischemic stroke occurred in 6 of 441 patients (1.4%) in the PFO closure group and in 12 of 223 patients (5.4%) in the antiplatelet-only group (hazard ratio, 0.23; 95% confidence interval [CI], 0.09 to 0.62; P=0.002). The incidence of new brain infarctions was significantly lower in the PFO closure group than in the antiplatelet-only group (22 patients [5.7%] vs. 20 patients [11.3%]; relative risk, 0.51; 95% CI, 0.29 to 0.91; P=0.04), but the incidence of silent brain infarction did not differ significantly between the study groups (P=0.97). Serious adverse events occurred in 23.1% of the patients in the PFO closure group and in 27.8% of the patients in the antiplatelet-only group (P=0.22). Serious device-related adverse events occurred in 6 patients (1.4%) in the PFO closure group, and atrial fibrillation occurred in 29 patients (6.6%) after PFO closure. CONCLUSIONS: Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone; however, PFO closure was associated with higher rates of device complications and atrial fibrillation. (Funded by W.L. Gore and Associates; Gore REDUCE ClinicalTrials.gov number, NCT00738894 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Self-citationSacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569
Self-citationGuidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
(2008) · Cerebrovascular Diseases · doi:10.1159/000131083 · Cited by 2,489
Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline
Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022066 · Cited by 2,313
Furie, K. L., Kasner, S. E., Adams, R. J., Albers, G. W., Bush, R. L., Fagan, S. C., Halperin, J. L., Johnston, S. C., Katzan, I., Kernan, W. N., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181f7d043 · Cited by 1,492
Self-citationMas, J.-L., Arquizan, C., Lamy, C., Zuber, M., Cabanes, L., Derumeaux, G., & Coste, J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011503 · Cited by 1,361
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
Furlan, A. J., Reisman, M., Massaro, J., Mauri, L., Adams, H., Albers, G. W., Felberg, R., Herrmann, H., Kar, S., Landzberg, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1009639 · Cited by 1,060
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
Carroll, J. D., Saver, J. L., Thaler, D. E., Smalling, R. W., Berry, S., MacDonald, L. A., Marks, D. S., & Tirschwell, D. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301440 · Cited by 983
Interatrial septal abnormalities and stroke: A meta-analysis of case-control studies
Overell, J. R., Bone, I., & Lees, K. R. (2000) · Neurology · doi:10.1212/wnl.55.8.1172 · Cited by 936
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
Meier, B., Kalesan, B., Mattle, H. P., Khattab, A. A., Hildick-Smith, D., Dudek, D., Andersen, G., Ibrahim, R., Schuler, G., Walton, A. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211716 · Cited by 920
Self-citationVermeer, S. E., Hollander, M., van Dijk, E. J., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2003) · Stroke · doi:10.1161/01.str.0000068408.82115.d2 · Cited by 883
Some comments on frequently used multiple endpoint adjustment methods in clinical trials
Sankoh, A. J., Huque, M. F., & Dubey, S. D. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19971130)16:22<2529::aid-sim692>3.0.co;2-j · Cited by 805
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke
Kent, D. M., Ruthazer, R., Weimar, C., Mas, J.-L., Serena, J., Homma, S., Di Angelantonio, E., Di Tullio, M. R., Lutz, J. S., Elkind, M. S. V., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a08d59 · Cited by 637
Lopez, O. L., Jagust, W. J., Dulberg, C., Becker, J. T., DeKosky, S. T., Fitzpatrick, A., Breitner, J., Lyketsos, C., Jones, B., Kawas, C., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.10.1394 · Cited by 477
Smith, E. E., Saposnik, G., Biessels, G. J., Doubal, F. N., Fornage, M., Gorelick, P. B., Greenberg, S. M., Higashida, R. T., Kasner, S. E., & Seshadri, S. (2017) · Stroke · doi:10.1161/str.0000000000000116 · Cited by 404
Self-citationKhairy, P., O'Donnell, C. P., & Landzberg, M. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-9-200311040-00010 · Cited by 388
Silent MRI infarcts and the risk of future stroke: The cardiovascular health study
Bernick, C., Kuller, L., Dulberg, C., Jr., W. T. L., Manolio, T., Beauchamp, N., Price, T., & for the Cardiovascular Health Study Collaborative Research Group* (2001) · Neurology · doi:10.1212/wnl.57.7.1222 · Cited by 350
Jones, W. J., Williams, L. S., & Meschia, J. F. (2001) · Stroke · doi:10.1161/hs1001.096191 · Cited by 213
Device Closure of Patent Foramen Ovale After Stroke
Kent, D. M., Dahabreh, I. J., Ruthazer, R., Furlan, A. J., Reisman, M., Carroll, J. D., Saver, J. L., Smalling, R. W., Jüni, P., Mattle, H. P., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.023 · Cited by 207
Messe, S. R., Gronseth, G., Kent, D. M., Kizer, J. R., Homma, S., Rosterman, L. R., & Kasner, S. E. (2016) · Neurology · doi:10.1212/wnl.0000000000002961 · Cited by 129
Self-citationSilent Brain Infarcts: A Review of MRI Diagnostic Criteria
Zhu, Y., Dufouil, C., Tzourio, C., & Chabriat, H. (2011) · Stroke · doi:10.1161/strokeaha.110.600114 · Cited by 122
Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients
Putaala, J., Haapaniemi, E., Kurkinen, M., Salonen, O. L. M., Kaste, M., & Tatlisumak, T. (2011) · Neurology · doi:10.1212/wnl.0b013e31821a44ad · Cited by 67
Still No Closure on the Question of PFO Closure
Messe, S. R., & Kent, D. M. (2013) · New England Journal of Medicine · doi:10.1056/nejme1301680 · Cited by 53
Cited by
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Campbell, B. C. V., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0118-8 · Cited by 1,750
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P., Wang, Y., Wang, Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802686 · Cited by 1,028
Self-citationFeske, S. K. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.07.027 · Cited by 822
Metadata
- Authors
- Søndergaard, L., Kasner, S. E., Rhodes, J. F., Andersen, G., Iversen, H. K., Nielsen-Kudsk, J. E., Settergren, M., Sjöstrand, C., Roine, R. O., Hildick-Smith, D., Spence, J. D., & Thomassen, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-14
- Volume
- 377
- Issue
- 11
- Pages
- 1033-1042
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2755497194
- Cited by
- 1,137
- References
- 23
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.